Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 370

1.

Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.

Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Hepatology. 2016 May 14. doi: 10.1002/hep.28638. [Epub ahead of print]

PMID:
27177928
2.

Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV.

Nault JC, Mami I, La Bella T, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Mol Ther. 2016 Apr;24(4):660-1. doi: 10.1038/mt.2016.47. No abstract available.

PMID:
27081717
3.

AAV2 and Hepatocellular Carcinoma.

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Hum Gene Ther. 2016 Mar;27(3):211-3. doi: 10.1089/hum.2016.002. No abstract available.

PMID:
26935016
4.

Liver transplantation for adenomatosis: European experience.

Chiche L, David A, Adam R, Oliverius MM, Klempnauer J, Vibert E, Colledan M, Lerut J, Mazzafero VV, Di-Sandro S, Laurent C, Scuderi V, Suc B, Troisi R, Bachelier P, Dumortier J, Gugenheim J, Mabrut JY, Gonzalez-Pinto I, Pruvot FR, Le-Treut YP, Navarro F, Ortiz-de-Urbina J, Salamé E, Spada M, Bioulac-Sage P.

Liver Transpl. 2016 Apr;22(4):516-26. doi: 10.1002/lt.24417.

PMID:
26919265
5.

Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.

Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ; International Liver Pathology Study Group.

Histopathology. 2016 Jun;68(7):953-67. doi: 10.1111/his.12957. Epub 2016 Apr 28. Review.

PMID:
26918878
6.

Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.

Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-Paul MC, Azoulay D, Mehdaoui D, Luciani A, Zafrani ES, Bioulac-Sage P, Zucman-Rossi J.

Mod Pathol. 2016 Jan;29(1):43-50. doi: 10.1038/modpathol.2015.119. Epub 2015 Oct 30.

PMID:
26516697
7.

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Nat Genet. 2015 Oct;47(10):1187-93. doi: 10.1038/ng.3389. Epub 2015 Aug 24.

PMID:
26301494
8.

Simultaneous occurrence of focal nodular hyperplasia and HNF1A-inactivated hepatocellular adenoma: a collision tumor simulating a composite FNH-HCA.

Shih A, Lauwers GY, Balabaud C, Bioulac-Sage P, Misdraji J.

Am J Surg Pathol. 2015 Sep;39(9):1296-300. doi: 10.1097/PAS.0000000000000477.

PMID:
26274031
9.

Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.

Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P, Tran Van Nhieu J, Slama R, Letoublon C, Zarski JP, Jouvin-Marche E, Marche PN, Leroy V.

Liver Int. 2016 Mar;36(3):434-44. doi: 10.1111/liv.12927. Epub 2015 Sep 29.

PMID:
26215124
10.

Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders.

Sempoux C, Paradis V, Komuta M, Wee A, Calderaro J, Balabaud C, Quaglia A, Bioulac-Sage P.

J Hepatol. 2015 Nov;63(5):1173-80. doi: 10.1016/j.jhep.2015.06.017. Epub 2015 Jun 25.

PMID:
26119687
11.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J.

Nat Genet. 2015 May;47(5):505-11. doi: 10.1038/ng.3252. Epub 2015 Mar 30.

12.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group.

Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16.

13.

Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio.

Rogier J, Roullet S, Cornélis F, Biais M, Quinart A, Revel P, Bioulac-Sage P, Le Bail B.

Liver Transpl. 2015 May;21(5):690-5. doi: 10.1002/lt.24105.

14.

BRAF V600E mutational status in bile duct adenomas and hamartomas.

Pujals A, Bioulac-Sage P, Castain C, Charpy C, Zafrani ES, Calderaro J.

Histopathology. 2015 Oct;67(4):562-7. doi: 10.1111/his.12674. Epub 2015 Mar 31.

PMID:
25704541
15.

Well-differentiated hepatocellular neoplasm of uncertain malignant potential.

Balabaud C, Bioulac-Sage P, Ferrell L, Kakar S, Paradis V, Quaglia A, Sempoux C, Thung S, Zucman-Rossi J.

Hum Pathol. 2015 Apr;46(4):634-5. doi: 10.1016/j.humpath.2014.10.029. Epub 2014 Dec 31. No abstract available.

PMID:
25661243
16.

Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach.

Blanc JF, Frulio N, Chiche L, Sempoux C, Annet L, Hubert C, Gouw AS, de Jong KP, Bioulac-Sage P, Balabaud C.

Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):180-7. doi: 10.1016/j.clinre.2014.10.003. Epub 2014 Nov 26.

PMID:
25434466
17.

Pictures of focal nodular hyperplasia and hepatocellular adenomas.

Sempoux C, Balabaud C, Bioulac-Sage P.

World J Hepatol. 2014 Aug 27;6(8):580-95. doi: 10.4254/wjh.v6.i8.580. Review.

18.

Integrative quantitative proteomics unveils proteostasis imbalance in human hepatocellular carcinoma developed on nonfibrotic livers.

Negroni L, Taouji S, Arma D, Pallares-Lupon N, Leong K, Beausang LA, Latterich M, Bossé R, Balabaud C, Schmitter JM, Bioulac-Sage P, Zucman-Rossi J, Rosenbaum J, Chevet E.

Mol Cell Proteomics. 2014 Dec;13(12):3473-83. doi: 10.1074/mcp.M114.043174. Epub 2014 Sep 15.

19.

Glutamine synthetase interpretation in hepatocellular adenoma.

Balabaud C, Bioulac-Sage P.

Virchows Arch. 2014 Oct;465(4):495-6. doi: 10.1007/s00428-014-1649-8. Epub 2014 Sep 13. No abstract available.

PMID:
25216583
20.

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.

Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M, Zucman-Rossi J.

Hepatology. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372. Epub 2014 Oct 27.

PMID:
25123086
Items per page

Supplemental Content

Loading ...
Write to the Help Desk